Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ATN-249 in Healthy Male Participants

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ATN-249 in Healthy Male Participants

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs ATN 249 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Attune Pharmaceuticals; Life Science Pharmaceuticals
  • Most Recent Events

    • 26 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top